A Multicentre, Randomised, Double-Blind, Parallel Group Comparison Of The Efficacy And Safety Of Transdermal Buprenorphine (Norspan'registered trade mark' BTDS) And Placebo In Patients With Postherpetic Neuralgia.
Phase of Trial: Phase III/IV
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Buprenorphine (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- Acronyms ASSET-PHN
- Sponsors Mundipharma GmbH
- 08 Jun 2016 Status changed from active, no longer recruiting to completed.
- 30 Aug 2013 Planned number of patients changed from 120 to 124 as reported by Australian New Zealand Clinical Trials Registry.
- 30 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.